Mr. Kris Weinberg reports

TELO GENOMICS REPORTS SUBSTANTIAL PROGRESS TOWARD CLINICAL LAUNCH OF TELOVIEW-SMM

Telo Genomics Corp. has provided an update on the planned launch of the TeloView-SMM (smouldering multiple myeloma) assay in the fourth quarter of this year. The test will be introduced to clinicians as a research use only (RUO) tool through Telo Genomics's new physician experience program. The program, designated as smart (smouldering multiple myeloma assessment of risk for transformation), is intended for oncology/hematology physicians and their staff in the United States to gain experience ordering and utilizing the TeloView SMM assay.

Telo Genomics's chief executive officer, Kris Weinberg, said: "The planned 2023 launch of smart along with recent presentations of data at ASCO and EHA are important steps in building Telo's commercial presence in the [United States]. Working with a select group of physicians and facilities, the smart program will gather information and feedback that are critical to the successful launch of TeloView-SMM."

About TeloView-SMM

TeloView-SMM has the potential to be an important tool for physicians managing the care of patients diagnosed with smouldering multiple myeloma. The proprietary assay (and associated platform technology) quantifies individual patients' risk of transformation/progression by measuring the 3-D structure and spatial organization of telomeres. This molecular signature identifies high-risk SMM patients who are likely to benefit from earlier treatment intervention. The larger subset of low-risk patients may not require immediate treatment and can be regularly monitored using the TeloView-SMM assay along with standard phenotypic measures. Over 200,000 patients in the United States are currently living with smouldering multiple myeloma. The TeloView-SMM assay has a potential total addressable market of over 500,000 tests per year.

About Telo Genomics Corp.

Telo Genomics is a clinical-stage high-complexity laboratory pioneering the most comprehensive telomere platform in the industry. The company has developed powerful predictive and prognostic assay tools in oncology and neurological disease. These applications are facilitated on a liquid biopsy platform that performs quantitative analysis of 3-D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability. The benefits of the TeloView platform have been substantiated in over 160 peer-reviewed publications and 30-plus clinical studies involving more than 3,000 patients.

We seek Safe Harbor.